Anatomy and Neuroscience - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 16
  • Item
    Thumbnail Image
    Modulation of human mesenchymal and pluripotent stem cell behavior using biophysical and biochemical cues: A review
    Ding, S ; Kingshott, P ; Thissen, H ; Pera, M ; Wang, P-Y (WILEY, 2017-02)
  • Item
    Thumbnail Image
    Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells
    Akopian, V ; Andrews, PW ; Beil, S ; Benvenisty, N ; Brehm, J ; Christie, M ; Ford, A ; Fox, V ; Gokhale, PJ ; Healy, L ; Holm, F ; Hovatta, O ; Knowles, BB ; Ludwig, TE ; McKay, RDG ; Miyazaki, T ; Nakatsuji, N ; Oh, SKW ; Pera, MF ; Rossant, J ; Stacey, GN ; Suemori, H (SPRINGER, 2010-04)
    There are many reports of defined culture systems for the propagation of human embryonic stem cells in the absence of feeder cell support, but no previous study has undertaken a multi-laboratory comparison of these diverse methodologies. In this study, five separate laboratories, each with experience in human embryonic stem cell culture, used a panel of ten embryonic stem cell lines (including WA09 as an index cell line common to all laboratories) to assess eight cell culture methods, with propagation in the presence of Knockout Serum Replacer, FGF-2, and mouse embryonic fibroblast feeder cell layers serving as a positive control. The cultures were assessed for up to ten passages for attachment, death, and differentiated morphology by phase contrast microscopy, for growth by serial cell counts, and for maintenance of stem cell surface marker expression by flow cytometry. Of the eight culture systems, only the control and those based on two commercial media, mTeSR1 and STEMPRO, supported maintenance of most cell lines for ten passages. Cultures grown in the remaining media failed before this point due to lack of attachment, cell death, or overt cell differentiation. Possible explanations for relative success of the commercial formulations in this study, and the lack of success with other formulations from academic groups compared to previously published results, include: the complex combination of growth factors present in the commercial preparations; improved development, manufacture, and quality control in the commercial products; differences in epigenetic adaptation to culture in vitro between different ES cell lines grown in different laboratories.
  • Item
    Thumbnail Image
    A Novel Dual-Color Reporter for Identifying Insulin-Producing Beta- Cells and Classifying Heterogeneity of Insulinoma Cell Lines
    Lee, NS ; Rohan, JG ; Zitting, M ; Kamath, S ; Weitz, A ; Sipos, A ; Salvaterra, PM ; Hasegawa, K ; Pera, M ; Chow, RH ; Lynn, FC (PUBLIC LIBRARY SCIENCE, 2012-04-18)
    Many research studies use immortalized cell lines as surrogates for primary beta- cells. We describe the production and use of a novel "indirect" dual-fluorescent reporter system that leads to mutually exclusive expression of EGFP in insulin-producing (INS(+)) beta-cells or mCherry in non-beta-cells. Our system uses the human insulin promoter to initiate a Cre-mediated shift in reporter color within a single transgene construct and is useful for FACS selection of cells from single cultures for further analysis. Application of our reporter to presumably clonal HIT-T15 insulinoma cells, as well as other presumably clonal lines, indicates that these cultures are in fact heterogeneous with respect to INS(+) phenotype. Our strategy could be easily applied to other cell- or tissue-specific promoters. We anticipate its utility for FACS purification of INS(+) and glucose-responsive beta-like-cells from primary human islet cell isolates or in vitro differentiated pluripotent stem cells.
  • Item
    Thumbnail Image
    Functional Characterization of Friedreich Ataxia iPS-Derived Neuronal Progenitors and Their Integration in the Adult Brain
    Bird, MJ ; Needham, K ; Frazier, AE ; van Rooijen, J ; Leung, J ; Hough, S ; Denham, M ; Thornton, ME ; Parish, CL ; Nayagam, BA ; Pera, M ; Thorburn, DR ; Thompson, LH ; Dottori, M ; Zheng, JC (PUBLIC LIBRARY SCIENCE, 2014-07-07)
    Friedreich ataxia (FRDA) is an autosomal recessive disease characterised by neurodegeneration and cardiomyopathy that is caused by an insufficiency of the mitochondrial protein, frataxin. Our previous studies described the generation of FRDA induced pluripotent stem cell lines (FA3 and FA4 iPS) that retained genetic characteristics of this disease. Here we extend these studies, showing that neural derivatives of FA iPS cells are able to differentiate into functional neurons, which don't show altered susceptibility to cell death, and have normal mitochondrial function. Furthermore, FA iPS-derived neural progenitors are able to differentiate into functional neurons and integrate in the nervous system when transplanted into the cerebellar regions of host adult rodent brain. These are the first studies to describe both in vitro and in vivo characterization of FA iPS-derived neurons and demonstrate their capacity to survive long term. These findings are highly significant for developing FRDA therapies using patient-derived stem cells.
  • Item
    Thumbnail Image
    Multipotent Caudal Neural Progenitors Derived from Human Pluripotent Stem Cells That Give Rise to Lineages of the Central and Peripheral Nervous System
    Denham, M ; Hasegawa, K ; Menheniott, T ; Rollo, B ; Zhang, D ; Hough, S ; Alshawaf, A ; Febbraro, F ; Ighaniyan, S ; Leung, J ; Elliott, DA ; Newgreen, DF ; Pera, MF ; Dottori, M (WILEY, 2015-06)
    The caudal neural plate is a distinct region of the embryo that gives rise to major progenitor lineages of the developing central and peripheral nervous system, including neural crest and floor plate cells. We show that dual inhibition of the glycogen synthase kinase 3β and activin/nodal pathways by small molecules differentiate human pluripotent stem cells (hPSCs) directly into a preneuroepithelial progenitor population we named "caudal neural progenitors" (CNPs). CNPs coexpress caudal neural plate and mesoderm markers, and, share high similarities to embryonic caudal neural plate cells in their lineage differentiation potential. Exposure of CNPs to BMP2/4, sonic hedgehog, or FGF2 signaling efficiently directs their fate to neural crest/roof plate cells, floor plate cells, and caudally specified neuroepithelial cells, respectively. Neural crest derived from CNPs differentiated to neural crest derivatives and demonstrated extensive migratory properties in vivo. Importantly, we also determined the key extrinsic factors specifying CNPs from human embryonic stem cell include FGF8, canonical WNT, and IGF1. Our studies are the first to identify a multipotent neural progenitor derived from hPSCs, that is the precursor for major neural lineages of the embryonic caudal neural tube.
  • Item
    Thumbnail Image
    Characterization of the retinal pigment epithelium in Friedreich ataxia.
    Crombie, DE ; Van Bergen, N ; Davidson, KC ; Anjomani Virmouni, S ; Mckelvie, PA ; Chrysostomou, V ; Conquest, A ; Corben, LA ; Pook, MA ; Kulkarni, T ; Trounce, IA ; Pera, MF ; Delatycki, MB ; Pébay, A (Elsevier BV, 2015-12)
    We assessed structural elements of the retina in individuals with Friedreich ataxia (FRDA) and in mouse models of FRDA, as well as functions of the retinal pigment epithelium (RPE) in FRDA using induced pluripotent stem cells (iPSCs). We analyzed the retina of the FRDA mouse models YG22R and YG8R containing a human FRATAXIN (FXN) transgene by histology. We complemented this work with post-mortem evaluation of eyes from FRDA patients. Finally, we derived RPE cells from patient FRDA-iPSCs to assess oxidative phosphorylation (OXPHOS) and phagocytosis. We showed that whilst the YG22R and YG8R mouse models display elements of retinal degeneration, they do not recapitulate the loss of retinal ganglion cells (RGCs) found in the human disease. Further, RPE cells differentiated from human FRDA-iPSCs showed normal OXPHOS and we did not observe functional impairment of the RPE in Humans.
  • Item
    Thumbnail Image
    BCL-XL Mediates the Strong Selective Advantage of a 20q11.21 Amplification Commonly Found in Human Embryonic Stem Cell Cultures
    Avery, S ; Hirst, AJ ; Baker, D ; Lim, CY ; Alagaratnam, S ; Skotheim, RI ; Lothe, RA ; Pera, MF ; Colman, A ; Robson, P ; Andrews, PW ; Knowles, BB (CELL PRESS, 2013-11-19)
    Human embryonic stem cells (hESCs) regularly acquire nonrandom genomic aberrations during culture, raising concerns about their safe therapeutic application. The International Stem Cell Initiative identified a copy number variant (CNV) amplification of chromosome 20q11.21 in 25% of hESC lines displaying a normal karyotype. By comparing four cell lines paired for the presence or absence of this CNV, we show that those containing this amplicon have higher population doubling rates, attributable to enhanced cell survival through resistance to apoptosis. Of the three genes encoded within the minimal amplicon and expressed in hESCs, only overexpression of BCL2L1 (BCL-XL isoform) provides control cells with growth characteristics similar to those of CNV-containing cells, whereas inhibition of BCL-XL suppresses the growth advantage of CNV cells, establishing BCL2L1 as a driver mutation. Amplification of the 20q11.21 region is also detectable in human embryonal carcinoma cell lines and some teratocarcinomas, linking this mutation with malignant transformation.
  • Item
    Thumbnail Image
    Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells
    Kim, J-H ; Kurtz, A ; Yuan, B-Z ; Zeng, F ; Lomax, G ; Loring, JF ; Crook, J ; Ju, JH ; Clarke, L ; Inamdar, MS ; Pera, M ; Firpo, MT ; Sheldon, M ; Rahman, N ; O'Shea, O ; Pranke, P ; Zhou, Q ; Isasi, R ; Rungsiwiwut, R ; Kawamata, S ; Oh, S ; Ludwig, T ; Masui, T ; Novak, TJ ; Takahashi, T ; Fujibuchi, W ; Koo, SK ; Stacey, GN (WILEY, 2017-11)
    This article summarizes the recent activity of the International Stem Cell Banking Initiative (ISCBI) held at the California Institute for Regenerative Medicine (CIRM) in California (June 26, 2016) and the Korean National Institutes for Health in Korea (October 19-20, 2016). Through the workshops, ISCBI is endeavoring to support a new paradigm for human medicine using pluripotent stem cells (hPSC) for cell therapies. Priority considerations for ISCBI include ensuring the safety and efficacy of a final cell therapy product and quality assured source materials, such as stem cells and primary donor cells. To these ends, ISCBI aims to promote global harmonization on quality and safety control of stem cells for research and the development of starting materials for cell therapies, with regular workshops involving hPSC banking centers, biologists, and regulatory bodies. Here, we provide a brief overview of two such recent activities, with summaries of key issues raised. Stem Cells Translational Medicine 2017;6:1956-1962.
  • Item
    Thumbnail Image
    Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells
    Bellmaine, SF ; Ovchinnikov, DA ; Manallack, DT ; Cuddy, CE ; Elefanty, AG ; Stanley, EG ; Wolvetang, EJ ; Williams, SJ ; Pera, M (ELIFE SCIENCES PUBLICATIONS LTD, 2017-09-08)
    Genetic analysis has revealed that the dual specificity protein kinase DYRK1A has multiple roles in the development of the central nervous system. Increased DYRK1A gene dosage, such as occurs in Down syndrome, is known to affect neural progenitor cell differentiation, while haploinsufficiency of DYRK1A is associated with severe microcephaly. Using a set of known and newly synthesized DYRK1A inhibitors, along with CRISPR-mediated gene activation and shRNA knockdown of DYRK1A, we show here that chemical inhibition or genetic knockdown of DYRK1A interferes with neural specification of human pluripotent stem cells, a process equating to the earliest stage of human brain development. Specifically, DYRK1A inhibition insulates the self-renewing subpopulation of human pluripotent stem cells from powerful signals that drive neural induction. Our results suggest a novel mechanism for the disruptive effects of the absence or haploinsufficiency of DYRK1A on early mammalian development, and reveal a requirement for DYRK1A in the acquisition of competence for differentiation in human pluripotent stem cells.
  • Item
    Thumbnail Image
    Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells
    Allison, TF ; Andrews, PW ; Avior, Y ; Barbaric, I ; Benvenisty, N ; Bock, C ; Brehm, J ; Bruestle, O ; Damjanov, I ; Elefanty, A ; Felkner, D ; Gokhale, PJ ; Halbritter, F ; Healy, LE ; Hu, TX ; Knowles, BB ; Loring, JF ; Ludwig, TE ; Mayberry, R ; Micallef, S ; Mohamed, JS ; Mueller, F-J ; Mummery, CL ; Nakatsuji, N ; Ng, ES ; Oh, SKW ; O'Shea, O ; Pera, MF ; Reubinoff, B ; Robson, P ; Rossant, J ; Schuldt, BM ; Solter, D ; Sourris, K ; Stacey, G ; Stanley, EG ; Suemori, H ; Takahashi, K ; Yamanaka, S (NATURE PUBLISHING GROUP, 2018-05-15)
    The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.